0O59.LSE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

Loading chart

Pay with

0O

Mkt Cap

N/A

Volume

376.07K

Next Earnings

N/A

Chart Earnings News About Dividends Insider Filings

Regeneron, Sanofi announce FDA approval of Dupixent for CSURegeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihista…finance.yahoo.com · Apr 19, 2025

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)Regeneron Pharmaceuticals, Inc. Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite …finance.yahoo.com · Apr 18, 2025

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaSanofi Winthrop Industrie Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more t…finance.yahoo.com · Apr 18, 2025

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movementTeigen to advocate for the importance of type 1 diabetes screening after son's diagnosis was uncovered during an unexpected medical emergency Screen For Type 1 movement continues momentum into year two with the goal of encouraging people to screen early; just one blood test can s…finance.yahoo.com · Apr 15, 2025

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDSanofi Winthrop Industrie Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addi…finance.yahoo.com · Apr 15, 2025

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here. President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fa…finance.yahoo.com · Apr 9, 2025

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisSanofi Winthrop Industrie Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multi…finance.yahoo.com · Apr 8, 2025

Tariffs Stoke Fears That Hung Debt Will Return(Bloomberg) -- Deals in leveraged finance have stalled, and markets have been upended, raising the possibility that banks might once again get stuck with debt they’ve committed for acquisitions. Most Read from Bloomberg Housing Agency Aims to Relocate Its DC Headquarters Local Go…finance.yahoo.com · Apr 5, 2025

Sanofi: Information concerning the total number of voting rights and shares - February 2025Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulatio…finance.yahoo.com · Apr 3, 2025

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesSanofi Winthrop Industrie Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU an…finance.yahoo.com · Apr 3, 2025

to start trading

0O

0O59.LSE0O59.LSE

0O59.LSE

Pay with—

Available Balance0.00

Your PositionYou don't own any 0O59.LSE yet.

Related Tickers

Earnings

Dividends

Last · May 5

Amount$4.12

Yield5.74%

Annual$4.12